Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

Shanthi Sivendran; Joe Goldufsky; Howard Kaufman; Yvonne Saenger

doi:10.1016/B978-0-12-394295-1.00015-9

Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

Shanthi Sivendran, Joe Goldufsky, Howard Kaufman, Yvonne Saenger

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.

Original language	English (US)
Title of host publication	Gene Therapy of Cancer
Subtitle of host publication	Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition
Publisher	Elsevier Inc.
Pages	213-223
Number of pages	11
ISBN (Print)	9780123942951
DOIs	https://doi.org/10.1016/B978-0-12-394295-1.00015-9
State	Published - Aug 2013
Externally published	Yes

Keywords

Advanced cancer
Herpes simplex virus
Immunotherapy
Oncolysis
Vaccin

ASJC Scopus subject areas

General Dentistry
General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/B978-0-12-394295-1.00015-9

Cite this

@inbook{335680b699d6426c89dadf73400377a1,

title = "Modified Oncolytic Herpesviruses for Gene Therapy of Cancer",

abstract = "Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.",

keywords = "Advanced cancer, Herpes simplex virus, Immunotherapy, Oncolysis, Vaccin",

author = "Shanthi Sivendran and Joe Goldufsky and Howard Kaufman and Yvonne Saenger",

year = "2013",

month = aug,

doi = "10.1016/B978-0-12-394295-1.00015-9",

language = "English (US)",

isbn = "9780123942951",

pages = "213--223",

booktitle = "Gene Therapy of Cancer",

publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

AU - Sivendran, Shanthi

AU - Goldufsky, Joe

AU - Kaufman, Howard

AU - Saenger, Yvonne

PY - 2013/8

Y1 - 2013/8

N2 - Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.

AB - Herpes simplex viruses (HSV) possess unique functions as both oncolytic vectors and vaccines capable of initiating an innate host antitumor immune response and have been developed for the gene therapy of cancer. Modifications of viral genes encoding pathogenicity and immunogenicity proteins and insertion of eukaryotic immune enhancing genes have resulted in viral strains with selective tumor oncolytic and potent immunization potential with an acceptable safety profile and no neurotoxicity. Several modified HSV vectors are currently in clinical trials, with the most experience in the treatment of advanced melanoma. In this chapter, we discuss the basic biology of HSV, describe the origin of individual oncolytic HSV strains in clinical use, and present the results of clinical trials for melanoma and other human cancers.

KW - Advanced cancer

KW - Herpes simplex virus

KW - Immunotherapy

KW - Oncolysis

KW - Vaccin

UR - http://www.scopus.com/inward/record.url?scp=84904079867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904079867&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-394295-1.00015-9

DO - 10.1016/B978-0-12-394295-1.00015-9

M3 - Chapter

AN - SCOPUS:84904079867

SN - 9780123942951

SP - 213

EP - 223

BT - Gene Therapy of Cancer

PB - Elsevier Inc.

ER -

Modified Oncolytic Herpesviruses for Gene Therapy of Cancer

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this